BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches

Thanks to cancer drugs Brukinsa and tislelizumab, BeiGene nearly doubled its global sales in 2022. But the most important launches for the meds either have just begun or are yet to come.